Drug Trial Radar · NCT03229564
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Oct 25, 2017
Primary completion
Nov 26, 2025
Study completion Jun 2028
Sponsor
- Lead sponsor
- CUTISS AGIndustry
- Sponsor type
- Industry
- Collaborators
- Wyss Zurich; Julius Clinical; Sintesi Research Srl; University Hospital, Zürich; University of Zurich
- First posted
- Jul 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase IIb trial aims to evaluate the efficacy and safety of EHSG-KF (synonym denovoSkin) in comparison to meshed STSG in children with partial deep dermal and full thickness burns.
Conditions
- Burns
Interventions
EHSG-KFBiological
Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
STSGBiological
Transplantation of autologous split-thickness skin graft to the control area
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of EHSG-KF in comparison to meshed STSG based on ratio of covered surfaceTime frame: 4 weeks post grafting
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Dipartimento di Chirurgia Pediatrica Ospedale dei bambini Vittorio Buzzi
Milan, Italy
Unità di Chirurgia Plastica e Ustioni Ospedale Santobono
Naples, Italy
Rode Kruis Ziekenhuis
Beverwijk, Netherlands
University Children's Hospital Zurich
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.